



## A total synthesis of (–)-antimycin A<sub>3b</sub>

Tetsuto Tsunoda,\* Takeshi Nishii, Makoto Yoshizuka, Chise Yamasaki, Tomonori Suzuki and Shô Itô

*Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima 770-8514, Japan*


Received 3 July 2000; accepted 28 July 2000

### Abstract

(–)-Antimycin A<sub>3b</sub>, the antipode of natural antibiotic antimycin A<sub>3b</sub>, was synthesized utilizing the asymmetric aza-Claisen rearrangement. © 2000 Elsevier Science Ltd. All rights reserved.

*Keywords:* asymmetric synthesis; aza-Claisen rearrangements; amides; antibiotics; lactonization.

(+)-Antimycin A<sub>3</sub> was isolated from *streptomyces* sp.<sup>1</sup> as a component of antimycin A complex (a mixture of A<sub>1</sub>–A<sub>8</sub>), which inhibited specifically the electron transfer activity of ubiquinol-cytochrome *c* oxidoreductase.<sup>2</sup> Among the components of antimycin A complex, A<sub>3</sub>, which is available from Sigma Co., is one of the most active agents and has been widely used in biological and biochemical investigations.<sup>3</sup>



(–)-Antimycin A<sub>3b</sub> ((–)-**1**)


Although the structure of antimycin A<sub>3</sub> had been established as 3-methylbutanoate (+)-**1** with a unique nine-membered dilactone structure, recent analytical investigations using HPLC disclosed that antimycin A<sub>3</sub> was in fact a mixture of (+)-**1**, now renamed antimycin A<sub>3b</sub>, and its acyloxy isomer at the 8-position, which is 2-methylbutanoate, named antimycin A<sub>3a</sub>.<sup>3b,4</sup> Since the separation of A<sub>3a</sub> and A<sub>3b</sub> is possible only with enormous effort, pure material of each component is practically available for biological and biochemical investigations.<sup>5,6</sup>

Antimycin A<sub>3b</sub> (previous name A<sub>3</sub>) has been an attractive target of synthetic efforts and a total synthesis<sup>7</sup> and its formal syntheses<sup>8</sup> have been accomplished. However, further effort to a

\* Corresponding author. Fax: +81-88-655-3051; e-mail: tsunoda@ph.bunri-u.ac.jp


practical and economical synthesis is still needed to supply sufficient amounts of pure antimycin A<sub>3b</sub> for biological or biochemical studies.

We have developed the asymmetric aza-Claisen rearrangement,<sup>9</sup> the thermal [3,3] sigmatropic rearrangement of the enolate of carboxamides **2** to **3** (Scheme 1), and demonstrated its applicability to straightforward short-step syntheses of natural products, including (-)-verrucarinolactone,<sup>10</sup> *D-allo*-isoleucine,<sup>10</sup> (-)-isoiridomyrmecin,<sup>11</sup> and (+)- $\alpha$ -skytanthine.<sup>12</sup> We applied the methodology to the synthesis of (-)-antimycin A<sub>3b</sub>, the antipode of this naturally occurring antibiotic, taking development of a practical synthetic route into consideration and having an interest in biological activities.<sup>13</sup> The result is reported herein.



Scheme 1.

(*R*)-(+)-Methylbenzylamine (**4**) was silylated with 1.0 equiv. of Me<sub>3</sub>SiOTf/DBU at 0°C. To the resulting mixture were added [(CH<sub>3</sub>)<sub>2</sub>CH]<sub>3</sub>SiOTf (TIPSOTf, 1.0 equiv.) and acrolein (1.0 equiv.) simultaneously to give the amine **5** (Scheme 2), in which the *E*-configuration of the olefinic double bond was verified by NMR spectroscopy. Acylation of **5** afforded the amide **6**, the precursor of the proposed aza-Claisen rearrangement. The rearrangement was carried out under standard conditions<sup>9</sup> to give the amides as a four stereoisomeric mixture, from which the major (*7S,8R*)-isomer **7a** was obtained by SiO<sub>2</sub> column chromatography as an inseparable 82:18 mixture with its (*7R,8S*)-isomer **7b** (78% combined yield).




Scheme 2. (a) (i) TMSOTf, DBU, ether, 0°C, 1 h; (ii) TIPSOTf, acrolein, ether, 0°C–rt, 6 h, 64%; (b) hexanoyl chloride, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0°C, 98%; (c) (i) LHMDS, toluene, -78°C; (ii) 120°C, 6 h, 78%; (d) I<sub>2</sub>, *N,N*-dimethyl-*p*-nitroaniline, DME–H<sub>2</sub>O (3:2), rt, 3 days, 78%; (e) Bu<sub>3</sub>SnH, PhH, reflux, 91%; (f) (i) CsOH, *t*-BuOH, 0°C; (ii) prenyl bromide, Py, ether, 0°C, 24 h, 40%

The iodolactonization<sup>14</sup> of the mixture **7a,b** afforded the iodo-lactone **8** (78%, enantiomeric mixture derived from **7a,b**) along with the stereoisomer **9** (4%), whose stereochemistry were

determined by NOE experiments. The lactone **8** was reduced with  $\text{Bu}_3\text{SnH}$  (2.4 equiv.) to **10**. After hydrolysis of **10** with 1 N  $\text{CsOH}$  aq. (1.0 equiv.) in *t*-BuOH, the solvent was evaporated and the residue was dried in a desiccator ( $\text{P}_2\text{O}_5$ ) under reduced pressure for 2 days. The resulting gummy oil was treated with prenyl bromide (3.0 equiv.) and pyridine (3.0 equiv.) in ether at  $0^\circ\text{C}^{15}$  to yield the prenyl ester **11** (40%) along with the butenolide **12** (40%).

The Mitsunobu reaction<sup>16</sup> of the hydroxy ester **11** with *N,O*-protected *D*-threonine **13** gave a diastereomeric mixture of the diester **14a** and its (7*R*,8*R*)-isomer **14b**<sup>17</sup> (Scheme 3). The TBDMS and the prenyl groups on the mixture **14a,b** were removed by acidic treatment, followed by a palladium-catalyzed reaction, affording the seco acids **15a,b**. The acids were converted into the dilactones **17a,b** in only 36% yield via the formation of the 2-pyridinethiol esters<sup>18</sup> **16a,b** and their treatment with  $\text{AgClO}_4$  at ambient temperature (the method of Gerlach)<sup>19</sup>. However, when the reaction mixture was heated under reflux for 2 h the yield increased dramatically to 82%. The diastereomer **17a** and **17b** were separated by  $\text{SiO}_2$  column chromatography.



Scheme 3. (g) **13**, DEAD- $\text{PPh}_3$ , PhH, rt, 24 h, 100%; (h) 6N HCl, EtOH, rt, 24 h, 95%; (i)  $\text{Pd}(\text{OAc})_2$ ,  $\text{PPh}_3$ ,  $\text{NEt}_3$ , HCOOH, dioxane,  $100^\circ\text{C}$ , 1 h, 85%; (j) 2,2'-dipyridyl disulfide,  $\text{PPh}_3$ , PhH, rt, 3 h, 99%; (k)  $\text{AgClO}_4$ , PhH,  $80^\circ\text{C}$ , 2 h, 82%; (l) TBAF, THF,  $0^\circ\text{C}$ , 5 min, 85%; (m) isovaleric anhydride, Py, 53%; (n)  $\text{H}_2$ , Pd-C, AcOEt, 67%; (o) **20**, WSC, HOBT, NMM, DMF, rt, 95%; (p)  $\text{H}_2$ , Pd-C, AcOEt, 89%

The *O*-isovalerylate **18** was obtained by quick treatment of **17a** with  $\text{Bu}_4\text{NF}$  at  $0^\circ\text{C}$ , followed by acylation with isovaleric anhydride. The cbz group of **18** was removed by the hydrogenolysis (Pd-C in ethyl acetate) to the amine **19**, which was successfully acylated with **20**, water-soluble carbodiimide (WSC), 1-hydroxybenzotriazole hydrate (HOBT), and *N*-methylmorpholine (NMM) in DMF to give the benzyl ether **21**. Hydrogenolysis of **21** with Pd-C in ethyl acetate led cleanly to (-)-antimycin  $\text{A}_{3b}$  [(-)-**1**]<sup>20</sup> in good yield, mp  $183.5\text{--}184.0^\circ\text{C}$ ,  $[\alpha]_{\text{D}}^{21} -74.2$  (*c* 0.98,  $\text{CHCl}_3$ ), whose physical properties compared well with those in the literature<sup>7b</sup> [mp  $183\text{--}185^\circ\text{C}$ ,  $[\alpha]_{\text{D}}^{24} +80$  (*c* 0.2,  $\text{CHCl}_3$ )].

Thus, the usefulness of the aza-Claisen rearrangement was amply demonstrated by the efficient synthesis of (–)-antimycin A<sub>3b</sub> [(–)-1]. Further synthetic studies of not only (–)-1 analogs but also (+)-1 analogs and the investigation of their biological activities are now in progress.

## Acknowledgements

This work was supported partially by a Sunbor Grant from the Suntory Institute for Bioorganic Research.

## References

- Dunshee, B. R.; Leben, C.; Keitt, G. W.; Strong, F. M. *J. Am. Chem. Soc.* **1949**, *71*, 2436–2437.
- Wikstrom, M. K. F.; Berden, J. A. *Biochim. Biophys. Acta* **1972**, *283*, 403–420.
- (a) Miyoshi, H.; Tokutake, N.; Imaeda, Y.; Akagi, T.; Iwamura, H. *Biochim. Biophys. Acta* **1995**, *1229*, 149–154. (b) Barrow, C. J.; Oleynek, J. J.; Marinelli, V.; Sun, H. H.; Kaplita, P.; Sedlock, D. M.; Gillum, A. M.; Chadwick, C. C.; Cooper, R. *J. Antibiot.* **1997**, *50*, 729–733. (c) Kim, H.; Esser, L.; Hossain, M. B.; Xia, D.; Yu, C. A.; Rizo, J.; van der Helm, D.; Deisenhofer, J. *J. Am. Chem. Soc.* **1999**, *121*, 4902–4903, and references cited therein.
- (a) Abidi, S. L. *J. Chromatogr.* **1988**, *447*, 65–79. (b) Abidi, S. L. *J. Chromatogr.* **1989**, *464*, 453–458.
- A NMR study in our laboratories disclosed that antimycin A<sub>3</sub> purchased from Sigma Co. was a 6:4 mixture of A<sub>3a</sub> and A<sub>3b</sub>.
- Deisenhofer reported with surprise that the ‘pure’ Antimycin A<sub>1</sub> purchased from Sigma Co. was in fact a mixture of A<sub>1a</sub> and A<sub>1b</sub>. See Ref. 3c.
- (a) Kinoshita, M.; Wada, M.; Aburaki, S.; Umezawa, S. *J. Antibiot.* **1971**, *24*, 724–726. (b) Kinoshita, M.; Aburaki, S.; Wada, M.; Umezawa, S. *Bull. Chem. Soc. Jpn.* **1973**, *46*, 1279–1287.
- (a) Aburaki, S.; Kinoshita, M. *Bull. Chem. Soc. Jpn.* **1979**, *52*, 198–203. (b) Nakata, T.; Fukui, M.; Oishi, T. *Tetrahedron Lett.* **1983**, *24*, 2657–2660. (c) Wasserman, H. H.; Gambale, R. J. *J. Am. Chem. Soc.* **1985**, *107*, 1423–1424. (d) Wasserman, H. H.; Gambale, R. J. *Tetrahedron* **1992**, *48*, 7059–7070. (e) Inghart, T.; Frejd, T. *Tetrahedron* **1991**, *47*, 6483–6492. (f) Kondo, H.; Oritani, T.; Kiyota, H. *Heterocycles* **2000**, *49*, in press.
- Tsunoda, T.; Sakai, M.; Sasaki, O.; Sako, Y.; Hondo, Y. *Tetrahedron Lett.* **1992**, *33*, 1651–1653.
- Tsunoda, T.; Tatsuki, S.; Shiraishi, Y.; Akasaka, M.; Itô, S. *Tetrahedron Lett.* **1993**, *34*, 3297–3300.
- Tsunoda, T.; Tatsuki, S.; Kataoka, K.; Itô, S. *Chem. Lett.* **1994**, 543–546. Itô, S.; Tsunoda, T. *Pure Appl. Chem.* **1994**, *66*, 2071–2074.
- Tsunoda, T.; Ozaki, F.; Shirakata, N.; Tamaoka, Y.; Yamamoto, H.; Itô, S. *Tetrahedron Lett.* **1996**, *37*, 2463–2466.
- (–)-Antimycin A<sub>3b</sub> had been synthesized once and had been compared with (+)-1 on inhibitory activity against electron transport of rat liver mitochondria. See, Miyoshi, H.; Kondo, H.; Oritani, T.; Saitoh, I.; Iwamura, H. *FEBS Lett.* **1991**, *292*, 61–63 and Ref. 8f.
- An addition of *N,N*-dimethyl-*p*-nitroaniline completely prevented the deprotection of TIPS ether linkage of **8** on Momose’s procedure. See, Takahata, H.; Uchida, Y.; Momose, T. *J. Org. Chem.* **1994**, *59*, 7201–7208.
- This new procedure can be applied to open lactone rings (Tsunoda, T.; Nishii, T.; Suzuki, T.; Itô, S., to be published).
- Mitsunobu, O. *Synthesis* **1981**, 1–28.
- 14b–17b** derived from **7b** were (7*R*,8*R*)-isomer of **14a–17a**, respectively.
- Endo, T.; Ikenaga, S.; Mukaiyama, T. *Bull. Chem. Soc. Jpn.* **1970**, *43*, 2632–2633.
- Gerlach, H.; Thalmann, A. *Helv. Chim. Acta* **1974**, *57*, 2661–2663. In this paper, a benzene solution of the pyridinthiol ester was treated with AgClO<sub>4</sub> (1.0 equiv.) at ambient temperature. Kinoshita had also reported that **16c** cyclized intramolecularly in a poor yield.<sup>7</sup>

20. (-)-Antimycin A<sub>3b</sub>: colorless needles (rotamer mixture): mp 183.5–184.0°C (ether/pet. ether);  $[\alpha]_D^{21}$  -74.2 (*c* 0.98, CHCl<sub>3</sub>): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  12.63 and 12.47 (total integr. 1H, s and br.s), 8.56 (1H, br.dd, *J*=8.1, 1.3 Hz), 8.52 (1H, d, *J*=1.8 Hz), 8.02 (1H, br.s), 7.25 (1H, dd, *J*=8.1, 1.3 Hz), 7.09 and 7.07 (total integr. 1H, br.d, *J*=7.8 Hz and br.d, *J*=7.8 Hz), 6.92 and 6.90 (total integr. 1H, t, *J*=8.1 Hz and t, *J*=7.8 Hz), 5.76 (1H, dq, *J*=7.8, 6.6 Hz), 5.32 and 5.29 (total integr. 1H, t, *J*=7.8 Hz and t, *J*=7.8 Hz), 5.12 and 5.16 (total integr. 1H, t, *J*=9.9 Hz and t, *J*=9.9 Hz), 4.98 (1H, dq, *J*=9.9, 6.3 Hz), 2.52 (1H, ddd, *J*=11.7, 9.9, 2.7 Hz), 2.26 (2H, d, *J*=7.8 Hz), 2.15 (1H, septet d, *J*=7.8, 6.3 Hz), 1.78–1.63 (1H, m), 1.43–1.04 (5H, m), 1.32 (3H, d, *J*=6.6 Hz), 1.30 (3H, d, *J*=6.3 Hz), 0.99 (6H, d, *J*=6.3 Hz), 0.87 (3H, t, *J*=7.8 Hz); IR (neat) 3370, 1750, 1692, 1644, 1611 cm<sup>-1</sup>; MS (CI) *m/z* 520 (M<sup>+</sup>), 458, 418, 264, 236, 220, 202 (bp); HMRS *m/z* 520.2454 (520.24206 calcd for C<sub>26</sub>H<sub>36</sub>N<sub>2</sub>O<sub>9</sub>).